Geode Capital Management LLC Purchases 21,196 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Geode Capital Management LLC grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 4.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 486,597 shares of the biotechnology company's stock after acquiring an additional 21,196 shares during the period. Geode Capital Management LLC owned about 1.60% of AnaptysBio worth $6,444,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ANAB. KLP Kapitalforvaltning AS bought a new position in AnaptysBio in the 4th quarter valued at approximately $40,000. AlphaQuest LLC boosted its position in shares of AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after buying an additional 4,237 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after buying an additional 644 shares in the last quarter. SG Americas Securities LLC raised its position in AnaptysBio by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company's stock worth $216,000 after buying an additional 4,231 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in AnaptysBio during the 4th quarter valued at about $311,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ANAB shares. JPMorgan Chase & Co. raised their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Wells Fargo & Company lifted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. HC Wainwright reissued a "neutral" rating and issued a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Finally, Guggenheim reissued a "buy" rating on shares of AnaptysBio in a report on Monday, March 3rd. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, AnaptysBio presently has an average rating of "Moderate Buy" and a consensus price target of $33.63.

AnaptysBio Stock Down 0.7 %

ANAB stock traded down $0.15 during trading on Tuesday, reaching $21.18. The company's stock had a trading volume of 346,034 shares, compared to its average volume of 595,494. The company's fifty day moving average is $17.96 and its 200-day moving average is $19.37. The company has a market capitalization of $649.53 million, a P/E ratio of -3.48 and a beta of -0.09. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. Analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has initiated a share repurchase plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.